SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Gilda Radner

PatientGilda Radner
Date of birth1986-06-28
IdentifiersMRN HR-ML026-SYN; SSN (made up) 000-26-8821
Document date2026-09-15
AuthorDelia Marchand, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End of chemotherapy: CT and CA-125 results, and the maintenance decision. [S]

History of Present Illness

Ms. Radner returns three weeks after her sixth and last cycle, all given on schedule. The CT a week ago shows no evidence of disease. Her energy is coming back, she walks most days, and her appetite is good. The tingling in her toes and fingertips is a little less than at cycle 4 and does not affect her hands or balance. Hot flashes continue at night. She saw Dr. Varghese with the CT result, and together they reviewed maintenance with olaparib, which she wants to start. She has no fever, cough, breathlessness, or bleeding. She has had no thoughts of self-harm. [S]

ElementDetail
TreatmentSix cycles of carboplatin and paclitaxel completed on schedule
ResponseCT: no evidence of disease; CA-125 9 U/mL
NeuropathyMild tingling, slowly improving
MenopauseHot flashes at night
DecisionStarts olaparib maintenance today

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improving; no fever or weight loss
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeNo nausea, bloating, or early fullness
NeurologicalPositiveMild tingling in the toes and fingertips, improving
EndocrinePositiveHot flashes at night
PsychiatricNegativeMood good; PHQ-9 3; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery40 mg under the skin once daily for 28 daysSubcutaneous route2026-04-21 to 2026-05-18completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-04-21 to 2026-05-05completedS
Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-05-12 to 2026-08-25completedS
Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route2026-05-12 to 2026-08-25completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route2026-05-12activeS
Olaparib 150 mg oral tablet, two tablets (300 mg) by mouth twice daily with food, as maintenance for up to two yearsTwo tablets twice daily with foodOral route2026-09-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-15Body height160cmS
2026-09-15Body weight56.8kgS
2026-09-15Body mass index (BMI) [Ratio]22.2kg/m2S
2026-09-15Systolic blood pressure114mm[Hg]S
2026-09-15Diastolic blood pressure72mm[Hg]S
2026-09-15Heart rate76/minS
2026-09-15Respiratory rate14/minS
2026-09-15Body temperature36.6CelS
2026-09-15Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-15Hemoglobin [Mass/volume] in Blood11.2g/dL11.6-15 g/dLLowS
2026-09-15Leukocytes [#/volume] in Blood by Automated count4.810*3/uL4-11 10*3/uLNormalS
2026-09-15Neutrophils [#/volume] in Blood by Automated count2.610*3/uL1.5-7.7 10*3/uLNormalS
2026-09-15Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
2026-09-15Creatinine [Mass/volume] in Serum or Plasma0.69mg/dL0.59-1.04 mg/dLNormalS
2026-09-15Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M113mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-15Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
2026-09-15Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
2026-09-15Cancer Ag 125 [Units/volume] in Serum or Plasma9U/mL<=35 U/mLNormalS
2026-09-15Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 2026-09-15; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 56.8 kg; blood pressure 114/72, pulse 76
AbdomenSoft, non-tender; no fluid or mass
Lymph nodesNo supraclavicular or inguinal nodes
NeurologicalPinprick slightly reduced over the toes only; vibration and reflexes normal; steady gait
PsychiatricBright and funny; organized

Problems

ProblemClinical statusVerificationCodeProvenance
Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the weekresolvedconfirmed R19.00S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation.
High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian canceractiveconfirmed C56.3S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D).
Peritoneal and omental metastases of the ovarian cancer, with ascitesactiveconfirmed C78.6S — Synthetic extent of disease on CT and biopsy.
Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is knownactiveconfirmed Z80.41S — Synthetic coding of her documented family history; the basis for genetic counseling.
Acute viral upper respiratory infection on day 8 of the second chemotherapy cycle: two days of sore throat, runny nose and a dry cough, without fever; rapid influenza and COVID-19 tests negative; resolvedresolvedconfirmed J06.9S — Synthetic acute infection; not a historical claim.
Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweatsactiveconfirmed E89.41S — Synthetic consequence of the synthetic operation.
Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes and fingertips, grade 1 (sensory only, no effect on daily activities)activeconfirmed G62.0S — Synthetic common effect of paclitaxel.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingResponse imaging (CT of the chest, abdomen and pelvis)At the end of primary treatmentUp to dateA week ago: no evidence of disease
LaboratoryCA-125At diagnosis; before each cycle when raised at diagnosis; at the end of treatment; then at each surveillance visitCompleted today9 U/mL, from 21 at cycle 4
LaboratoryBlood count before a PARP inhibitorBaseline, then monthly for the first yearCompleted todayHemoglobin 11.2 g/dL, white cells 4.8, neutrophils 2.6, platelets 214; recovered from chemotherapy
LaboratoryKidney and liver function before a PARP inhibitorBaseline, then as indicatedCompleted todayCreatinine 0.69 mg/dL, eGFR 113; ALT 19 U/L, bilirubin 0.4 mg/dL; no dose change needed
Medication safetyOlaparib safety: interactions, nausea and fatigue, anemia, pneumonitis, and the rare risk of a bone marrow disorderAt the start and each visitCompleted todayNo strong CYP3A inhibitors or inducers; no grapefruit; counseled on symptoms to report; ondansetron for nausea
LaboratoryMonthly blood count on olaparibMonthly for the first yearOrderedFirst check in four weeks, at the preventive visit
ExaminationPeripheral neuropathy: symptoms and examinationAt each visit after taxane treatmentCompleted todayGrade 1, improving
SurveyDistress and depression screen (PHQ-9)At diagnosis, at each treatment phase, and when symptoms changeCompleted todayPHQ-9 3
Self-managementMenopausal symptoms after oophorectomyEach visit after surgeryCompleted todayHot flashes at night; hormone therapy discussed and deferred by her choice
ImagingBone density (baseline after surgical menopause)Once after treatment, then by resultDueTo be ordered at the preventive visit next month
Self-managementSurvivorship care planAt the end of treatmentCompleted todayWritten plan given: visits every three months for two years with examination and CA-125, symptoms to report (bloating, early fullness, pelvic or abdominal pain, change in bowel habit), and support resources

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020); Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Preventive visit in four weeks with the first monthly blood count. Gynecologic oncology surveillance every three months. Call for breathlessness, new cough, fever, bruising, or the return of bloating or early fullness. Next scheduled visit 2026-10-13: periodic adult preventive visit after ovarian cancer treatment. [S]